Hemab Therapeutics

Hemab Therapeutics

  • Founded: 2021
  • Location: Copenhagen, Denmark
  • Employee range: 11 - 50
  • Clinical stage: Clin1/Clin2
  • Therapy area: Glanzmann Thrombasthenia
  • Drug types: HEM, GEN, RAR
  • Lead product: HMB-001
  • Product link: https://hemab.com/#pipeline
  • Funding: $135M B Feb 2023; $55M Jul 2021
  • Investors: Access Biotechnology, Deep Track Capital, Avoro Capital, Invus, Rock Springs Capital, Maj Invest Equity, Novo Holdings, RA Capital Management, HealthCap



job board

Short description:

Bleeding Disorder Treatments

Drug notes:

HMB-VWF Clin0 bleeding disorders; HMB-TAF Clin0 bleeding disorders; HMB-AT3 RD thrombosis; HMB-TBA RD undisclosed

Long description:

Hemab Therapeutics is developing therapeutics for patients with rare bleeding and thrombotic disorders. The body’s bleeding and thrombosis pathway is fine-tuned with numerous points within that can fail and cause disease. Hemab is using technological advancements to provide prophylactic treatments and functional cures for the full spectrum of genetically driven bleeding and thrombotic disorders. The therapeutic candidates bind the body’s native clotting factors with high specificity and affinity to balance endogenous clotting factors to the point of injury. Hemab is working to develop five clinical assets by 2025.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com